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Background: Polymyositis (PM) and dermatomyositis (DM) are idiopathic inflammatory myopathies. Genetic
variability in human leukocyte antigen (HLA) genes plays an important role in the pathogenesis of PM and DM.
However, few studies on the subject in Chinese populations have been reported thus far.
Methods: We studied the influence of HLA polymorphisms on DM and PM susceptibility by analyzing HLA-DRB1,
HLA-DQA1, and HLA-DQB1 alleles in 71 adult DM patients, 20 adult PM patients, and 113 controls in a Han Chinese
population.
Results: A positive association was found between HLA-DQA1*0104 and DM (p = 0.01; corrected p (pcorr) NS;
odds ratio (OR) = 2.58; 95% confidence interval (CI): 1.18–5.64), while an inverse correlation was noted between
HLA-DQB1*0303 and myositis patients with interstitial lung inflammation (p = 0.01; pcorr NS; OR = 0.25; 95% CI:
0.07–0.73). A positive relationship was also observed between HLA-DRB1*07 and DM (p = 0.01; pcorr NS; OR = 2.26;
95% CI: 1.12–4.59), while HLA-DRB1*03 seems to be protective against DM (p = 0.01; pcorr NS; OR = 0.26; 95% CI:
0.06–0.81). The lung complication was closely associated with HLA-DRB1*04 (p = 0.01; pcorr NS; OR = 2.82; 95% CI:
1.15–6.76) and HLA-DRB1*12 (p = 0.02; pcorr NS; OR = 2.52; 95% CI: 1.02–6.07). The frequency of HLA-DRB1*07 was
significantly higher among myositis patients with dysphagia than among controls (p = 0.01; pcorr NS; OR = 4.78;
95% CI: 1.03–24.42). The putative haplotype DRB1*07-DQA1*01-DQB1*02 was positively correlated with DM (p = 0.03;
pcorr NS; OR = 2.90; 95% CI: 1.02–8.93) and the lung complication (p = 0.02; pcorr NS; OR = 3.45; 95% CI: 1.04–11.58).
Conclusions: Our results demonstrate that HLA alleles may be involved in susceptibility to adult DM and PM in the
Han Chinese population.
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Polymyositis (PM) and dermatomyositis (DM) are idio-
pathic inflammatory myopathies (IIM), a group of autoim-
mune disorders characterized by inflammation present
predominantly in muscle tissues. The chief clinical pre-
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[1]. Although the underlying pathogenesis for PM and
DM remains unclear, evidence has suggested that, like
many other autoimmune conditions, these disorders likely
result from a combination of environmental exposure and
genetic susceptibility [2]. Genetic variability in the human
leukocyte antigen (HLA) genes is thought to play an im-
portant role in DM and PM pathogenesis [3,4]. This may
be partly attributed to the influence of HLA molecules on
T-cell receptor development, peripheral tolerance, and
immune response to environmental agents. It has been
established that geographic locations and ethnicities may
affect susceptibility to autoimmune diseases [5,6]. The. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reported as risk factors for myositis in Western popula-
tions [7,8], whereas DRB1*0803 may increase PM suscep-
tibility among the Japanese population [9]. In studies of 52
DM and PM patients from Northern China, Han et al. re-
ported positive associations between the HLA-DRB1*04,
HLA-DRB1*07, and HLA-DRB1*12 alleles and DM devel-
opment [10]. They also observed that HLA-DQB1*0401 is
a risk factor for DM and PM [11]. However, the sample
sizes of these studies were small; therefore, the possible
role of HLA class II alleles in myopathies in Chinese pa-
tients requires further investigation.
To assess the effect of polymorphisms in HLA-DRB1,
HLA-DQA1, and HLA-DQB1 on DM and PM suscepti-
bility, we conducted a study of 91 adult patients with
DM or PM and 113 healthy controls in a Han Chinese
population. Our results demonstrate that HLA class II
alleles may influence adult DM and PM susceptibility in
the Han Chinese population.
Methods
Study subjects
Between August 2009 and March 2012, 71 and 20 pa-
tients were diagnosed with DM and PM, respectively, at
the Huashan Hospital of Fudan University in Shanghai,
China. The patients met probable or definite diagnosis
of DM or PM according to the Bohan and Peter [12]
criteria [12,13]. Lung lesions were examined by chest
computed tomography, and a diagnosis of interstitial
lung disease (ILD) or idiopathic interstitial pneumon-
itis was made by a pulmonologist. All patients were
ethnic Han Chinese (25 males and 66 females, median age
of 51 ± 15.8 years). One hundred and thirteen healthy Han
Chinese subjects (36 males and 77 females, median age of
40.0 ± 8.6 years) with no history of autoimmune disease
were enrolled in the study as controls. The study followed
protocols set by the Declaration of Helsinki and was ap-
proved by the ethics committee of Huashan Hospital. All
patients and controls provided written informed consent
prior to the study.
Experiments
DNA was extracted from blood using the Qiagen DNA
extraction kit (Qiagen; Hilden, Germany). Low- and high-
resolution typing of the HLA-DRB1, HLA-DQA1, and
HLA-DQB1 alleles were performed using the polymerase
chain reaction (PCR)-sequence-specific primed (SSP) pro-
cedure described by Olerup et al. [14,15]. Serum was
obtained from all patients for detection of myositis-
specific antibodies (MSA; anti-Jo-1 autoantibodies) and
myositis-associated antibodies (MAA; anti-Ro and anti-La
autoantibodies). Autoantibodies were analyzed by an in-
direct immunofluorescence method using the kits from
EUROIMMUN AG (Lubeck, Germany).Statistical analysis
The allele, genotype, and haplotype frequencies of the
HLA loci were compared between the patients and con-
trols using the Fisher exact test or chi-square test, as ap-
propriate. Data were expressed as odds ratios (ORs) with
95% confidence intervals (CIs). A p-value ≤ 0.05 was con-
sidered statistically significant. In multiple comparisons,
p-values were adjusted using the Bonferroni correction to
give a corrected p-value (pcorr). A p-value ≤ 0.05 before
correction for multiple comparisons was considered as
possibly statistically significant. The Hardy–Weinberg
equilibrium constant in the control group was confirmed
using a chi-square test. Putative haplotypes were inferred
from unphased genotype data using the Bayesian sta-
tistical method available in the PHASE program v2.1.1
[16]. Putative haplotypes with a frequency higher than 3%
among the controls were selected for further compari-
sons between the patients and controls. Unless otherwise
stated, Stata (version 7.0; Stata Corp.; College Station, TX,
USA) statistical software was used to perform the statis-
tical analyses.
Results
Of the 91 patients, 71 had been diagnosed with DM and
20 with PM (66 female and 25 male [2.64:1]). Although
most of the patients were positive for antinuclear anti-
bodies, few were positive for either MSA or MAA. The
frequencies of MSA and MAA were higher in the PM
group than in the DM group (10% vs. 1.4%, p = 0.06 for
MSA; 20% vs. 5.63%, p = 0.05 for MAA). As expected,
cutaneous involvement such as rash or cuticular over-
growth was present only in DM patients. Approximately
half of the patients had ILD, with a higher prevalence
among patients with PM than those with DM (76.5%
vs. 37.7%, p = 0.04). No significant differences in other
clinical features were observed between the two groups
(Table 1).
Genotyping analyses of the HLA-DQA1 and HLA-
DQB1 loci were performed to study the relationship bet-
ween the HLA class II alleles and susceptibility to DM
and PM. Because there are several lines of evidence to
suggest that DM and PM may be distinct diseases with
different genetic backgrounds [17], we analyzed the in-
fluence of the HLA alleles on susceptibility to DM and
PM individually rather than analyzing the combined
DM/PM group (Table 2). Compared with the controls,
the frequency of HLA-DQA1*0104 was significantly higher
in the DM group than in the PM group (16.42% vs. 8.18%,
p = 0.01, pcorr NS; OR = 2.58; 95% CI: 1.18–5.74), implying
a possible positive correlation between HLA-DQA1*0104
and the risk of DM. Of the HLA-DQB1 alleles analyzed,
only the HLA-DQB1*0303 frequency was lower in patients
with ILD than in the controls (6.76% vs. 19.03%, p = 0.01,
pcorr NS; OR = 0.25; 95% CI: 0.07 − 0.73), implying that








MSA (anti-Jo-1) 1 (1.4) 2 (10) 0.06
MAA (SSA, SSB or Scl) 4 (5.63) 4 (20) 0.05
Clinical presentations
Fever 4 (5.6) 1 (5) 0.92
Raynaud’s disease 0.00 1 (5) 0.06
Arthritis 1 (1.4) 0.00 0.59
Interstitial lung disease 261 (37.7) 132 (76.5) 0.04
Palpitations 1 (1.4) 0.00 0.59
Dysphagia 10 (14.1) 4 (20) 0.51
V-sign 26 (36.6) 0.00 n/a
Gottron papules 24 (33.8) 0.00 n/a
Periorbital edematous rash 11 (15.5) 0.00 n/a
Shawl sign 13 (18.3) 0.00 n/a
Cuticular overgrowth 3 (4.2) 0.00 n/a
MSA: myositosis-specific autoantiboides; MAA: myositosis associated
autoantibodies;
169 DM patients evaluated; 217 PM patients evaluated; n/a: not applicable.
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complication. This was further confirmed by the fact that
the HLA-DQB1*0303 frequency was lower among those
who developed ILD (p < 0.01; OR = 0.19; 95% CI: 0.038–
0.37) than those who did not develop ILD. HLA-DRB1
typing analysis showed that compared to controls, DM
patients had a considerably lower prevalence of HLA-
DRB1*03 (3.08% vs. 11.27%, p = 0.01, pcorr NS; OR = 0.26;
95% CI: 0.06–0.81) and a higher frequency of HLA-
DRB1*07 (20.77% vs. 13.24%, p = 0.01, pcorr NS, OR = 2.26,
95% CI, 1.12–4.59). Both HLA-DRB1*04 and HLA-
DRB1*12 alleles are likely linked to the lung disease (p =
0.01, pcorr NS; OR = 2.82; 95% CI: 1.15–6.76 and p = 0.02,
pcorr NS; OR = 2.52; 95% CI: 1.02–6.07, respectively). A
similar effect of HLA-DRB1*04 on ILD development was
also observed when the allele frequencies between patients
with and without the lung complication were compared
(p = 0.026; OR = 3.32; 95% CI: 1.22–9.08). Comparison of
HLA-DRB1*12 allele frequencies between myositis pa-
tients with and without ILD showed a similar trend of be-
ing higher among those with ILD than among those
without, although the difference between the two groups
was not statistically significant (p = 0.35; OR = 1.59;
95% CI: 0.63–4.00). This is likely attributable to the
small numbers in the groups examined. Moreover, the
HLA-DRB1*07 allele showed a possible influence on the
development of esophageal/muscle complications (30.00%
vs. 13.24%, p = 0.01, pcorr NS; OR = 4.78; 95% CI: 1.03–
24.42). A similar trend for a higher HLA-DRB1*07 al-
lele frequency was also noted among patients who haddysphagia as compared to those who did not (p = 0.057;
OR = 3.55; 95% CI: 0.91–13.82).
We then examined the association between putative
haplotypes involving the DRB1-DQA1-DQB1 loci and
susceptibility to DM, PM, lung, and esophageal com-
plications. In this analysis, only the putative haplotypes
present in at least 3% of the controls were selected for
further study. Of the 12 putative haplotypes selected, the
frequency of DRB1*07-DQA1*01-DQB1*02 was higher
in the DM group (p = 0.03, pcorr NS; OR = 2.90; 95% CI:
1.02–8.93) and in patients with ILD (p = 0.02, pcorr NS;
OR = 3.45; 95% CI: 1.04–11.58) than in the controls, in-
dicating that this putative haplotype might increase the
risk of DM and the lung complication (Table 3). A fur-
ther comparison of the DRB1*07-DQA1*01-DQB1*02
frequency in patients who developed dysphagia with
those who did not showed a trend for a higher frequency
of this haplotype among patients with dysphagia, although
the difference between the groups was not statistically sig-
nificant (p = 0.23; OR = 2.27; 95% CI: 0.68–7.72). Again,
we consider that this result is likely due to the small sam-
ple sizes in both groups.
Discussion
There are differences in the clinical features of DM and
PM between our cohort of Han Chinese patients and
Western patients [1,18]. There are more DM cases in our
cohort and among Mesoamerican patients, whereas PM is
the major subtype among Caucasian patients [19]. Com-
pared to Caucasian patients, our cohort had a higher pre-
valence of the lung complication [20]. The frequencies
of dysphagia were comparable between our cohort and
those reported in the West [1,21]. Approximately 30–40%
of Caucasian and African American IIM patients are posi-
tive for MSA/MAA autoantibodies [19,22]. Although the
proportion of patients who were positive for autoanti-
bodies was relatively low in our cohort, it is nonethe-
less comparable to findings from other studies in Chinese
patients [23,24].
There is a growing body of evidence to suggest that
differences in the impact of HLA class II alleles on the
susceptibility to DM and PM may exist among different
ethnic groups and geographic locations [19,20,25-27]. It
has been well documented that HLA class II alleles that
form the 8.1 ancestral haplotype (8.1 AH), DRB1*03-
DQA1*05-DQB1*02, are closely linked to DM and PM in
Western populations [4,7,28]. Previous studies suggest
that HLA-DQA1*0501 and HLA-DRB1*0301 may be risk
factors for PM, whereas HLA-DQA1*0201 and HLA-
DRB1*0401 confer protection against the disease in
Caucasians [4,28-30]. Moreover, HLA-DRB1*07 has been
reported to protect against PM and IIM in Caucasians
and African Americans [4,22,28]. In their study of
African American patients with IIM, O’Hanlon et al. [22]







Control Control vs. indicated patients (p; OR (95% CI))




HLA-DRB1 N = 65 N = 19 N = 37 N = 10 N = 113
*01 1 (0.77) 0 (0.00) 1 (1.35) 0 (0.00) 5 (2.45) n/s n/a n/s n/a
*03 4 (3.08) 4 (10.53) 4 (5.41) 1 (5.00) 23 (11.27) 0.011; 0.26 n/s n/s n/s
(0.06–0.81)
*04 17 (13.08) 6 (15.79) 15 (20.27) 2 (10.00) 22 (10.78) n/s n/s 0.011; 2.82 n/s
(1.15–6.76)
*07 27 (20.77) 1 (2.63) 14 (18.92) 6 (30.00) 27 (13.24) 0.011; 2.26 n/s n/s 0.011; 4.78
(1.12–4.59) (1.03–24.42)
*08 13 (10.00) 4 (10.53) 7 (9.46) 2 (10.00) 17 (8.33) n/s n/s n/s n/s
*09 20 (15.38) 2 (5.26) 3 (4.05) 3 (15.00) 26 (12.75) n/s n/s n/s n/s
*10 2 (1.54) 1 (2.63) 2 (2.70) 0 (0.00) 3 (1.47) n/s n/s n/s n/a
*11 3 (2.31) 3 (7.89) 2 (2.70) 0 (0.00) 9 (4.41) n/s n/s n/s n/a
*12 20 (15.38) 7 (18.42) 14 (18.92) 1 (5.00) 22 (10.78) n/s n/s 0.021; 2.52 n/s
(1.02–6.07)
*13 7 (5.38) 1 (2.63) 2 (2.70) 1 (5.00) 8 (3.92) n/s n/s n/s n/s
*14 2 (1.54) 3 (7.89) 1 (1.35) 2 (10.00) 9 (4.41) n/s n/s n/s n/s
*15 10 (7.69) 4 (10.53) 7 (9.46) 1 (5.00) 29 (14.22) n/s n/s n/s n/s
*16 4 (3.08) 2 (5.26) 2 (2.70) 1 (5.00) 4 (1.96) n/s n/s n/s n/s
HLA-DQA1 N = 67 N = 20 N = 39 N = 12 N = 110
*0101 9 (6.72) 0 (0.00) 5 (6.41) 1 (4.17) 11 (5.00) n/s n/a n/s n/s
*0102 18 (13.43) 10 (25.00) 16 (20.51) 4 (16.67) 44 (20.00) n/s n/s n/s n/s
*0103 26 (19.40) 6 (15.00) 10 (12.82) 6 (25.00) 28 (12.73) n/s n/s n/s n/s
*0104 22 (16.42) 4 (10.00) 11 (14.10) 4 (16.67) 18 (8.18) 0.011; 2.58 n/s n/s n/s
1.18–5.64)
*0201 1 (0.75) 2 (5.00) 1 (1.28) 0 (0.00) 1 (0.45) n/s n/s n/s n/a
*0301 44 (32.84) 9 (22.50) 26 (33.33) 9 (37.50) 85 (38.64) n/s n/s n/s n/s
*0302 1 (0.75) 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.45) n/s n/a n/a n/a
*0401 1 (0.75) 2 (5.00) 2 (2.56) 0 (0.00) 3 (1.36) n/s n/s n/s n/a
*0501 11 (8.21) 6 (15.00) 6 (7.69) 0 (0.00) 28 (12.73) n/s n/s n/s n/a
*0507 1 (0.75) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) n/a n/a n/a n/a
*0601 0 (0.00) 1 (2.50) 1 (1.28) 0 (0.00) 1 (0.45) n/a n/s
HLA-DQB1 N = 67 N = 17 N = 37 N = 10 N = 113
*0201 31 (23.48) 6 (16.67) 16 (21.62) 5 (25.00) 44 (19.47) n/s n/s n/s n/s
*0301 20 (15.15) 9 (25.00) 15 (20.27) 0 (0.00) 35 (15.49) n./s n/s n/s n/a
*0302 9 (6.82) 2 (5.56) 7 (9.46) 1 (5.00) 12 (5.31) n/s n/s n/s n/s
*0303 24 (18.18) 2 (5.56) 5 (6.76) 5 (25.00) 43 (19.03) n/s n/s 0.011; 0.25 n/s
(0.07–0.73)
*0401 6 (4.55) 2 (5.56) 6 (8.11) 1 (5.00) 7 (3.10) n/s n/s n/s n/s
*0402 0 (0.00) 1 (2.78) 1 (1.35) 0 (0.00) 1 (0.44) n.a. n/s n/s n/a
*0501 1 (0.76) 2 (5.56) 3 (4.05) 0 (0.00) 8 (3.54) n/s n/s n/s n/a
*0502 5 (3.79) 2 (5.56) 5 (6.76) 0 (0.00) 7 (3.10) n/s n/s n/s n/a
*0503 4(3.03) 1 (2.78) 0 (0.00) 2 (10.00) 8 (3.54) n/s n/s n/a n/s
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Table 2 HLA-DQA1, HLA-DQB1, and HLA-DRB1 allele frequencies in PM and DM patients and controls (Continued)
*0601 20 (15.15) 7 (19.44) 11 (14.86) 3 (15.00) 33 (14.60) n/s n/s n/s n/s
*0602 4 (3.03) 2 (5.56) 2 (2.70) 2 (10.00) 16 (7.08) n/s n/s n/s n/s
*0604 5 (3.79) 0 (0.00) 2 (2.70) 0 (0.00) 5 (2.21) n/s n/a n/s n/a
*0608 3 (2.27) 0 (0.00) 1 (1.35) 1 (5.00) 7 (3.10) n/s n/a n/s n/s
n/s: not significant; n/a: not applicable; 1pcorr greater than 0.05; ILD: interstitial lung disease.
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increase the risk of DM, while HLA-DRB1*0301 influences
PM susceptibility. Furuya et al. [9,26] found that both
HLA-DRB1*0803 and HLA-DQA1*0501 provide an in-
creased risk of DM but a reduced risk of PM in a Japanese
population. In a study of 25 Korean patients with IIM,
Rider et al. [27] reported that HLA-DRB1*14 as a protect-
ive factor for DM and PM. To date, most studies on the
subject have been focused on Western populations. In
their studies of 52 DM and PM patients from Northern
China, Han et al. reported that HLA-DRB1*04, HLA-
DRB1*07, and HLA-DRB1*12 may render an increased
risk of DM [10], while HLA-DQB1*0401 may have an im-
pact on IIM susceptibility [11]. Our data demonstrate that
the HLA-DQA1*0104 and HLA-DRB1*07 alleles are likely
associated with an increased risk of DM, whereas HLA-
DRB1*03 may provide protection against DM. Although
8.1 AH is known as a risk factor for IIM among indi-
viduals of Northwestern European descent [4,7,28], such
an association has not been established in other ethnic
groups [25]. DRB1*03-DQA1*05-DQB1*02 is not a ma-
jor haplotype in our cohort and does not influence DM
and PM susceptibility. Our results suggest that the HLA-Table 3 Comparisons of frequencies of HLA class II putative h




DRB1-DQA1-DQB1 n (%) n (%) n (%) N = 36 n (%), N
03-05-02 2 (1.59) 2 (5.56) 2 (2.78) 0 (0.00
04-03-03 6 (4.36) 1 (2.78) 5 (6.94) 1 (5.56
04-03-04 5 (3.97) 2 (5.56) 5 (6.94) 1 (5.56
07-01-02 12 (9.52) 1 (2.78) 8 (11.11) 2 (11.11
07-03-02 6 (4.76) 0 (0.00) 3 (4.17) 2 (11.11
08-01-06 13 (10.32) 3 (8.33) 6 (8.33) 2 (11.11
09-03-03 17 (13.49) 2 (5.56) 3 (4.17) 3 (16.67
11-05-03 3 (2.38) 1 (2.78) 1 (1.39) 0 (0.00
12-01-03 11 (8.73) 2 (5.56) 8 (11.11) 0 (0.00
13-01-06 7 (5.56) 0 (0.00) 2 (2.78) 1 (5.56
14-01-05 2 (1.59) 1 (2.78) 0 (0.00) 2 (11.11
15-01-06 7 (5.56) 3 (8.33) 3 (4.17) 1 (5.56
n/s: not significant; n/a: not applicable; 1pcorr greater than 0.05; ILD: interstitial lungDRB1*07-DQA1*01-DQB1*02 haplotype may be associ-
ated with DM and ILD.
It is interesting to note that HLA-DRB1*07 influences
IIM susceptibility among various ethnic groups. In our
study of Han Chinese patients, the HLA-DRB1*07 allele in
the putative haplotype DRB1*07-DQA1*01-DQB1*02 was
found to be a risk factor for DM, but the same allele
present in the DRB1*07-DQA1*02-DQB1*02 haplotype
was reported to be a protector against IIM in Caucasians
and African Americans [4,22,25,28]. These findings imply
that HLA-DRB1*07 might have opposite effects on the dis-
eases in different ethnic groups. Similar phenomena have
been observed for the effect of HLA-DQA1*0501 on IIM.
This allele was reported as a protective factor against IIM
in a Japanese population [9] but as a risk factor for IIM
among US Caucasians [29]. Although it is unclear what
might cause such different effects, possible explanations
include referral bias, small sample sizes resulting in non-
representative populations, different pathogeneses, various
environmental risk triggers around the world, and uniden-
tified genetic loci responsible for disease development.
Furuya et al. [26] reported a positive relationship between
HLA-DRB1*0405 and anti-aminoacyl-tRNA synthetaseaplotypes between DM and PM and controls
ith
ia
Control (N =100) Controls vs. indicated patients
(p; OR [95% CI])




) 11 (5.50) n/s n/s n/s n/s
) 9 (4.50) n/s n/s n/s n/s
) 6 (3.00) n/s n/s n/s n/s
) 7 (3.50) 0.031; 2.90 n/s 0.021; 3.45 n/s
(1.02–8.93) (1.04–11.58)
) 11 (5.50) n/s n/s n/s n/s
) 13 (6.50) n/s n/s n/s n/s
) 20 (10.00) n/s n/s n/s n/s
) 7 (3.50) n/s n/s n/s n/s
) 11 (5.50) n/s n/s n/s n/s
) 7 (3.50) n/s n/s n/s n/s
) 7 (3.50) n/s n/s n/s n/s
) 19 (9.50) n/s n/s n/s n/s
disease.
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O’Hanlon et al. found that the HLA-DRB1*0302 allele is
closely linked to myositis-specific anti-Mi-2 autoanti-
bodies in DM [4]. In our study, the numbers of patients
with MSA and MAA were too small to have sufficient
statistical power for further analysis of the relationship
between HLA alleles and MSA/MAA autoantibodies. It
is also noteworthy that a greater frequency of myositis
autoantibodies was found among PM patients from our
cohort and the cohort reported by Chinoy and col-
leagues [20]. However, both cohorts were small in size,
and in our study we analyzed only a limited number of
autoantibodies.
Previous studies suggest that DM and PM may have
different pathogeneses. It has been proposed that DM is
likely the result of an autoimmune process induced by a
humoral response, whereas PM may be caused by a cell-
mediated autoimmune process [17]. Thus, it is plausible
that DM and PM might have distinctive genetic suscep-
tibilities. Further investigation is warranted to better un-
derstand the pathogeneses of these two diseases.
Possible explanations for the differences between the
results from our study and those from other studies in-
clude the fact that the studies were conducted in different
geographic locations with various environmental expo-
sures, the heterogeneity in genetic backgrounds among
the different ethnic groups and populations, the num-
ber of HLA polymorphic alleles analyzed, the different
study methodologies used, referral bias, and the age
and sex composition of the different study cohorts. The
differences in the clinical and immunogenetic features
between adult and childhood DM and PM are well
documented [8,31].
Our study has some limitations. Although DM and
PM are rare conditions and the number of patients in
our cohort is the largest compared with similar studies
in Chinese patients, it is still a relatively small cohort. It
is likely that there are many genes and genetic polymor-
phisms that may influence DM and PM susceptibility,
and we analyzed only a few of them. The data from our
study should be validated by further analysis of multiple
genes and alleles and their combined impacts on disease
susceptibility. Nevertheless, our data shed some light on
the genetic susceptibility of adult DM and PM, and may
aid in stratifying disease subtypes according to genetic
and ethnic backgrounds.Conclusions
Our study of adult DM and PM in a Chinese population
demonstrated that the putative haplotype DRB1*07-
DQA1*01-DQB1*02 and the DRB1*07 and DQA1*0104
alleles are associated with an increased risk of DM,
while DRB1*03 is associated with a reduced risk ofDM. DQB1*0303 may confer protection against the lung
complication, and DRB1*04, DRB1*12, and DRB1*07-
DQA1*01-DQB1*02 are associated with an increased
risk of developing the lung complication. Furthermore,
DRB1*07 is associated with an increased risk of develop-
ing dysphagia.
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